His primary areas of study are Internal medicine, Immunology, Surgery, Telomerase and Molecular biology. His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine. His Immunology research includes themes of Case-control study and Oncology.
He interconnects Young adult, Malignancy and Histopathology in the investigation of issues within Surgery. His Telomerase research includes elements of Telomere, Malignant transformation and Cellular differentiation. His Molecular biology study combines topics from a wide range of disciplines, such as Chromatin immunoprecipitation and Transactivation.
Magnus Björkholm focuses on Internal medicine, Immunology, Surgery, Oncology and Gastroenterology. His study in Internal medicine concentrates on Multiple myeloma, Hematology, Chemotherapy, Lymphoma and Cancer. His biological study spans a wide range of topics, including Cancer research and Telomerase reverse transcriptase.
His study in Immunology focuses on Lymphocyte, Antibody, Leukemia, Antigen and Chronic lymphocytic leukemia. His Lymphocyte study combines topics in areas such as Concanavalin A, Pokeweed mitogen, Disease and DNA synthesis. His work carried out in the field of Leukemia brings together such families of science as Myeloid and Myeloid leukemia.
Magnus Björkholm mainly investigates Internal medicine, Oncology, Cancer research, Cancer and Immunology. His studies deal with areas such as Gastroenterology and Surgery as well as Internal medicine. His study on Oncology also encompasses disciplines like
His Cancer research research is multidisciplinary, relying on both Carcinogenesis, DNA methylation and Telomerase, Telomerase reverse transcriptase. His Telomerase study incorporates themes from Telomere and Molecular biology. The study incorporates disciplines such as Odds ratio, Pathology, Population based study and Genetic predisposition in addition to Cancer.
His primary scientific interests are in Internal medicine, Cancer, Oncology, Cancer research and Surgery. His research related to Hematology, Relative survival, Case-control study, Multiple myeloma and Hazard ratio might be considered part of Internal medicine. His study in Cancer is interdisciplinary in nature, drawing from both Myotonic dystrophy and Cause of death.
His Oncology research incorporates themes from Head and neck cancer, Malignancy, Immunology and Cohort. His Immunology research is multidisciplinary, incorporating perspectives in Haematopoiesis and Chemotherapy. His research integrates issues of TaqMan, Urine and Telomerase, Telomerase reverse transcriptase in his study of Cancer research.
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Jeanette Lundin;Eva Kimby;Magnus Björkholm;Per-Anders Broliden.
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower;Magnus Björkholm;Paul W. Dickman;Martin Höglund.
Journal of Clinical Oncology (2016)
Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells.
Dawei Xu;Nikita Popov;Mi Hou;Qian Wang.
Proceedings of the National Academy of Sciences of the United States of America (2001)
INTERFERON THERAPY IN MYELOMATOSIS
H Mellstedt;M Björkholm;B Johansson;A Ahre.
The Lancet (1979)
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
Sigurdur Yngvi Kristinsson;Ola Landgren;Paul W. Dickman;Åsa Rangert Derolf.
Journal of Clinical Oncology (2007)
Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells
Dawei Xu;Qian Wang;Astrid Gruber;Magnus Björkholm.
Acute myeloid leukaemia.
Asim Khwaja;Magnus Bjorkholm;Rosemary E Gale;Ross L Levine.
Nature Reviews Disease Primers (2016)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Ola Landgren;Ola Landgren;Lynn R. Goldin;Sigurdur Y. Kristinsson;Elin A. Helgadottir.
Risk of haematopoietic cancer in patients with inflammatory bowel disease.
J Askling;L Brandt;A Lapidus;P Karlén.
Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes
Sigurdur Y. Kristinsson;Magnus Björkholm;Malin Hultcrantz;Åsa R. Derolf.
Journal of Clinical Oncology (2011)
If you think any of the details on this page are incorrect, let us know.